Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), incorporated in Ireland, filed this Current Report on November 6, 2019. The filing announces the release of earnings results for the third quarter ended September 28, 2019. The full earnings press release is attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for non-GAAP financial measures used in the accompanying press release.
Management utilizes non-GAAP measures to evaluate ongoing operating trends, excluding items such as:
- Amortization of acquired intangible assets
- Restructuring and acquisition integration charges
- Impairment charges and asset abandonment
- Losses on investment securities and early debt extinguishment
- Operating results from held-for-sale businesses (Animal Health, Infant Foods)
- Foreign currency translation movements
Material Changes and Unusual Items
A significant adjustment for the quarter ended September 28, 2019, relates to the industry-wide ranitidine market withdrawal. The Company adjusted its results to reverse returns, inventory writedowns, and other costs associated with this event. Management states these adjustments increase adjusted net sales and profit measures to better reflect underlying operational performance, noting that the recall is not reflective of the Company's specific operating trends.
Comparisons to the prior period (ended June 30, 2018) also exclude similar non-recurring items and divestitures.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance or numerical outlooks. Management commentary emphasizes that product recalls occur periodically in the industry and may recur in the future. However, the Company continues to manufacture and sell other products treating the same conditions as ranitidine.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures.
- Verify the magnitude of the ranitidine market withdrawal adjustments on net sales and profit.
- Confirm the impact of foreign currency translation on reported growth rates.
- Assess the status of held-for-sale businesses (Animal Health and Infant Foods) excluded from adjusted sales.
- Monitor future disclosures regarding potential product recalls or litigation.